Literature DB >> 12855228

Congenital disorder of glycosylation Ic in patients of Indian origin.

J W Newell1, N-S Seo, G M Enns, M McCraken, J F Mantovani, H H Freeze.   

Abstract

Congenital disorder of glycosylation type Ic (CDG-Ic) is caused by mutations in ALG6, encoding an alpha 1,3-glucosyltransferase. The most frequent mutation found in this gene (C998T resulting in an A333V substitution) has until now been found only in patients of European origin. Here we describe the first occurrence of this CDG-Ic mutation in patients of Indian origin. Of three Indian patients described in this study, patient 1 was homozygous and patient 2 heterozygous for the A333V mutation. In patient 2 we also found a new mutation, IVS3+2_3insT, just 3bp away from the previously described IVS3+5G>A substitution; both mutations resulted in exon 3 skipping. We screened a panel of >350 genomic DNA samples from an ethnically diverse American population to determine the frequency of the A333V mutation. None of the samples carried this mutation, indicating the frequency of patients carrying this homozygous mutation should be <1 in 5x10(5). The discovery of the common CDG-Ic mutation A333V in an Indian population raises questions as to its ethnic origin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12855228     DOI: 10.1016/s1096-7192(03)00089-1

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  9 in total

1.  ALG6-CDG in South Africa: Genotype-Phenotype Description of Five Novel Patients.

Authors:  M Dercksen; A C Crutchley; E M Honey; M M Lippert; G Matthijs; L J Mienie; H C Schuman; B C Vorster; J Jaeken
Journal:  JIMD Rep       Date:  2012-07-01

2.  Clinical utility gene card for: ALG6 defective congenital disorder of glycosylation.

Authors:  Jaak Jaeken; Dirk Lefeber; Gert Matthijs
Journal:  Eur J Hum Genet       Date:  2014-07-23       Impact factor: 4.246

3.  Reduced expression of the oligosaccharyltransferase exacerbates protein hypoglycosylation in cells lacking the fully assembled oligosaccharide donor.

Authors:  Shiteshu Shrimal; Reid Gilmore
Journal:  Glycobiology       Date:  2015-03-19       Impact factor: 4.313

4.  Employment of single-strand conformation polymorphism analysis in screening for α-1,3 glucosyltransferase gene mutation A333V in Croatian population.

Authors:  Sandra Supraha Goreta; Sanja Dabelic; Jerka Dumic
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

5.  Genome-wide linkage and copy number variation analysis reveals 710 kb duplication on chromosome 1p31.3 responsible for autosomal dominant omphalocele.

Authors:  Uppala Radhakrishna; Swapan K Nath; Ken McElreavey; Uppala Ratnamala; Celi Sun; Amit K Maiti; Maryline Gagnebin; Frédérique Béna; Heather L Newkirk; Andrew J Sharp; David B Everman; Jeffrey C Murray; Charles E Schwartz; Stylianos E Antonarakis; Merlin G Butler
Journal:  J Med Genet       Date:  2012-04       Impact factor: 6.318

6.  Comparison of transferrin isoform analysis by capillary electrophoresis and HPLC for screening congenital disorders of glycosylation.

Authors:  Mihika B Dave; Alpa J Dherai; Vrajesh P Udani; Anaita U Hegde; Neelu A Desai; Tester F Ashavaid
Journal:  J Clin Lab Anal       Date:  2017-02-25       Impact factor: 2.352

7.  Frequency Determination of α-1,3 Glucosyltransferase p.Y131H and p.F304S Polymorphisms in the Croatian Population Revealed Five Novel Single Nucleotide Polymorphisms in the hALG6 Gene.

Authors:  Sandra Supraha Goreta; Sanja Dabelic; Dinko Pavlinic; Gordan Lauc; Jerka Dumic
Journal:  Genet Test Mol Biomarkers       Date:  2011-09-07

8.  Congenital disorder of glycosylation type Ia in a Malaysian family: clinical outcome and description of a novel PMM2 mutation.

Authors:  M K Thong; M Fietz; C Nicholls; M H Lee; O Asma
Journal:  J Inherit Metab Dis       Date:  2009-01-26       Impact factor: 4.982

Review 9.  Insights into complexity of congenital disorders of glycosylation.

Authors:  Sandra Supraha Goreta; Sanja Dabelic; Jerka Dumic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.